Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00451048 · OUTCOME

Overall Survival

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia · Source last updated 2018-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
At 6 months and 1 year

Groups in this outcome

Arm I

Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown. sunitinib malate: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I5

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I13.9Not reported9.7NA95% confidence - 9.7 months to not reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        95% confidence - 9.7 months to not reached
        group Id
        OG000
        lower Limit
        9.7
        upper Limit
        NA
        value
        13.9
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown. sunitinib malate: Given orally
    id
    OG000
    title
    Arm I
param Type
MEDIAN
reporting Status
POSTED
time Frame
At 6 months and 1 year
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice